Estimates of subgroup treatment effects in overall nonsignificant trials: To what extent should we believe in them?
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 280, doi. 10.1002/pst.1810
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2017 AND VI 16 AND IP 4
Results: 6
1
2
Covariate-adjusted borrowing of historical control data in randomized clinical trials.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 296, doi. 10.1002/pst.1815
- By:
- Publication type:
- Article
3
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 229, doi. 10.1002/pst.1784
- Publication type:
- Article
4
Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 232, doi. 10.1002/pst.1807
- By:
- Publication type:
- Article
5
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 250, doi. 10.1002/pst.1808
- By:
- Publication type:
- Article
6
The time-dependent 'cure-death' model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 4, p. 267, doi. 10.1002/pst.1809
- By:
- Publication type:
- Article